Silverback Therapeutics (SBTX) Competitors $17.65 -0.33 (-1.84%) As of 08/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SBTX vs. CALT, MENS, ZYME, MBX, AVTE, NLTX, CYBN, BIOA, VIRI, and WHWKShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Jyong Biotech (MENS), Zymeworks (ZYME), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). Silverback Therapeutics vs. Its Competitors Calliditas Therapeutics AB (publ) Jyong Biotech Zymeworks MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics Silverback Therapeutics (NASDAQ:SBTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Do institutionals & insiders have more ownership in SBTX or CALT? 74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is SBTX or CALT more profitable? Silverback Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Silverback Therapeutics' return on equity of -29.62% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has more volatility and risk, SBTX or CALT? Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Which has preferable earnings & valuation, SBTX or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Silverback Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-7.29Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the media refer more to SBTX or CALT? In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Calliditas Therapeutics AB (publ)'saverage media sentiment score. Company Overall Sentiment Silverback Therapeutics Neutral Calliditas Therapeutics AB (publ) Neutral SummarySilverback Therapeutics and Calliditas Therapeutics AB (publ) tied by winning 5 of the 10 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$636.42M$790.06M$5.46B$9.67BDividend YieldN/A4.84%3.99%4.14%P/E Ratio-7.291.3129.9924.97Price / SalesN/A25.16375.5577.11Price / CashN/A19.5635.9458.58Price / Book2.386.558.165.68Net Income-$89.48M-$4.07M$3.25B$265.38M7 Day Performance-0.17%0.27%1.11%2.52%1 Month Performance3.28%4.81%2.80%1.86%1 Year Performance78.46%24.85%28.49%24.21% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$17.65-1.8%N/A+88.0%$636.42MN/A-7.2983High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MENSJyong BiotechN/A$15.04+3.9%N/AN/A$1.14BN/A0.0031ZYMEZymeworks3.274 of 5 stars$13.52+0.4%$21.00+55.4%+23.7%$942.67M$93.38M-9.02460News CoverageEarnings ReportGap UpMBXMBX Biosciences2.7387 of 5 stars$14.64+0.6%$37.57+156.7%N/A$487.49MN/A0.0036News CoverageAnalyst ForecastAVTEAerovate TherapeuticsN/A$7.75-6.4%N/A-86.6%$224.63MN/A-2.5920Upcoming EarningsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-43.8%$203.75MN/A-6.9790CYBNCybin2.8669 of 5 stars$7.53-2.7%$85.00+1,028.8%N/A$177.04MN/A-1.7150Positive NewsBIOABioAge LabsN/A$4.43-2.2%N/AN/A$158.82MN/A0.00N/AEarnings ReportVIRIVirios TherapeuticsN/A$4.82+1.0%$5.00+3.7%+2,497.4%$92.82MN/A-17.855News CoverageWHWKWhitehawk TherapeuticsN/A$1.78-1.7%N/AN/A$83.86M$25.98M11.1340News CoverageEarnings Report Related Companies and Tools Related Companies CALT Alternatives MENS Alternatives ZYME Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBTX Stock Alerts